

## This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
<b>Neurology</b>				
Neurology	Notch 1 (NOTCH1)	<p>Mouse studies suggest inhibiting NOTCH1 could help treat indications involving neuronal loss. In a mouse model of stroke, neuronal levels of Notch1 and other components of the Notch signaling pathway were lower than pre-stroke baselines and were accompanied by neurogenesis in striatal astrocytes, which was blocked by forced expression of <i>Notch1</i>. In normal mice, knockout of Notch1 signaling pathway components in striatal astrocytes increased neurogenesis compared with normal Notch1 signaling. Next steps include evaluating whether promoting astrocyte-mediated neurogenesis in the striatum could treat mouse models of undisclosed neurological diseases.</p> <p>OncoMed Pharmaceuticals Inc. has OMP-52M51, a humanized IgG2 mAb against NOTCH1, in Phase I testing to treat various cancers.</p> <p>At least two other companies have NOTCH1-inhibiting compounds in preclinical development for cancer.</p> <p><b>SciBX 7(43); doi:10.1038/scibx.2014.1269</b>  <b>Published online Nov. 6, 2014</b></p>	Unpatented; licensing status not applicable	<p>Magnusson, J.P. <i>et al. Science</i>; published online Oct. 9, 2014;            doi:10.1126/science.346.6206.237  <b>Contact:</b> Jonas Frisén, Karolinska Institute, Stockholm, Sweden            e-mail:  <a href="mailto:jonas.frisen@ki.se">jonas.frisen@ki.se</a></p>